VIDEO: Sozinibercept combination therapy shows promising visual acuity gains in wet AMD
Click Here to Manage Email Alerts
BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Timothy L. Jackson, PhD, MBChB, discusses phase 2b trial results of sozinibercept for neovascular age-related macular degeneration.
Sozinibercept (Opthea) targets VEGF-C and VEGF-D and is meant to be used in combination with the VEGF-A-suppressing drugs ranibizumab or aflibercept. In the trial, two different doses of sozinibercept were used in combination with ranibizumab and showed superior efficacy with the higher dose as compared with ranibizumab monotherapy.
“It was exciting to see a drug that was offering an improved visual acuity rather than what most trials are going for at the moment, which is just fewer injections,” Jackson said.
Two phase 3 trials of sozinibercept are currently underway: ShORe, which is evaluating sozinibercept in combination with ranibizumab, and COAST, which is evaluating sozinibercept in combination with aflibercept.
Collapse
Jackson T. Role of VEGF-C and D inhibition in age-related macular degeneration. Presented at: Euretina congress; Sept. 19-22, 2024; Barcelona, Spain.
Click Here to Manage Email Alerts